Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...
Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...
TipRanks on MSN
Recursion appoints Najat Khan as CEO, effective January 1
Recursion announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026: Najat ...
Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...
SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback